http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yu, Lan,Park, Ji Sun,Lim, Yun-Soo,Lee, Churl Seung,Shin, Kwonwoo,Moon, Ho Jun,Yang, Cheol-Min,Lee, Young Sil,Han, Jong Hun IOP Pub 2013 Nanotechnology Vol.24 No.15
<P>Carbon nanomaterials are generally used to promote the thermal conductivity of polymer composites. However, individual graphene nanoplatelets (GNPs) or carbon nanotubes (CNTs) limit the realization of the desirable thermal conductivity of the composite in both through- and in-plane directions. In this work, we present the thermal conductivity enhancement of the epoxy composite with carbon hybrid fillers composed of CNTs directly grown on the GNP support. The composite with 20 wt% hybrid filler loading showed 300% and 50% through-plane thermal conductivity improvements in comparison with the individual CNTs and GNPs, respectively. Moreover, it showed an enhanced thermal conductivity of up to 12% higher than that of the simply mixed GNP and CNT fillers. In more detail, hybrid fillers, whose CNTs were synthesized on the GNP support (Support C, Fe/Mo–MgO:GNP=1:0.456) for 60 min via chemical vapor deposition process, presented the highest through-plane thermal conductivity of 2.41 W m<SUP>−1</SUP> K<SUP>−1</SUP> in an epoxy composite.</P>
Yu, Min,Liu, Lei,Zhang, Bing-Lan,Chen, Qi,Ma, Xue-Lei,Wu, Yu-Ke,Liang, Chun-Shui,Niu, Zhi-Min,Qin, Xin,Niu, Ting Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.12
Background: This study was performed to analyze the prognostic implications of pretreatment or preoperative thrombocytosis in women with gynecologic malignancies. Material and Methods: We surveyed 2 medical databases, PubMed and EMBASE, to identified all relevant studies. A total of 14 (n=3,490) that evaluated the link between thrombocytosis and 5-year survival were included. REVMAN version 5.1 was used for our analysis and publication bias was evaluated using the Begg's funnel plot and tested by STATA 11.0. Risk ratios (RRs) with 95% confidence intervals (CIs) generated by the random effect model were used to assess the strength of any association. Results: 709(20.3%) of the 3,490 patients exhibited thrombocytosis (platelet counts > $400{\times}10^9/L$) at primary diagnosis, and their mortality was 1.62-fold higher compared with the others (RR=1.62, 95%CI=[1.28-2.05], p<0.0001). Thrombocytosis failed to have a stronger effect on the survival of advanced patients of stages III to IV in our study (n=478, RR=1.29, 95% CI=[1.13-1.48], p=0.0003), nor in women with cervical cancer in stage IB (n=1371, RR=1.73, 95% CI=[1.71-2.58], p=0.007). In addition, when adjusted for different carcinoma, it was associated with worse prognosis for all except the ones with vulvar cancer (n=201, RR=0.43, 95% CI=[0.14-1.29], p=0.13). Conclusions: This meta-analysis indicated that thrombocytosis might be associated with a worse prognosis for patients with gynecologic malignancies but without specificity or sensitivity for the ones in advanced stage. When adjusted for different gynecologic malignancies, it showed a significant effect on survival of all except vulvar cancers.
Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
Min-Yu Lan,Hui-Chen Lin,Tsung-Hui Hu,Shu-Fang Chen,Chien-Hung Chen,Yung-Yee Chang,King-Wah Chiu,Tsu-Kung Lin,Shun-Sheng Chen 대한신경과학회 2023 Journal of Clinical Neurology Vol.19 No.1
Background and Purpose Oral nucleos(t)ide analogs (NAs) are the mainstay treatment for chronic hepatitis B (CHB). Myotoxicity is an important extrahepatic effect related to NA treatment. Telbivudine is the NA for CHB that is frequently associated with muscle-related side effects. The risk factors for telbivudine-induced myopathy (TIM) are not yet clear. Methods This study characterized the clinical, magnetic resonance images (MRI), and pathological features of 12 TIM cases. A group of telbivudine-tolerant (TT) patients with CHB who received regular telbivudine treatment during the same period without the occurrence of myopathy was collected. Demographic and clinical factors were compared between the patients with TIM and the TT controls. Factors independently associated with TIM were identified using logistic regression analysis. Results The patients with TIM (males/females: 7/5, mean age: 57 years) developed myopathy after using telbivudine for a median period of 19.5 months. Muscle histopathology revealed abnormal proliferation, subsarcolemmal or sarcoplasmic accumulations, and ultrastructural defects of mitochondria. When compared with TT cases, patients with TIM had a lower estimated glomerular filtration rate and were more frequently positive for hepatitis B e antigen (HBeAg). Conclusions Mitochondrial abnormalities are characteristic histopathological features, and impaired renal function and HBeAg positivity are risk factors for TIM. Telbivudine-induced mitochondrial dysfunction and immune activation related to mitochondrial damage and HBeAg serostatus changes may underlie TIM. Constant clinical surveillance of myopathy during telbivudine treatment is needed due to the significant latency of its development. Dose adjustment for impaired renal function does not eliminate the risk of TIM occurrence.
( Ya-min Lai ),( Wei-yan Yao ),( Yao He ),( Xuan Jiang ),( Yu-bei Gu ),( Min-hu Chen ),( Yu-lan Liu ),( Yao-zong Yuan ),( Jia-ming Qian ) 대한소화기학회 2017 Gut and Liver Vol.11 No.2
Background/Aims: Patients with active ulcerative colitis (UC) have elevated levels of activated myeloid-derived leukocytes as a source of inflammatory cytokines. The selective deple-tion of these leukocytes by adsorptive granulocyte/monocyte apheresis (GMA) with an Adacolumn should alleviate inflammation, promote remission and enhance drug efficacy. However, studies have reported contrasting efficacy out-comes based on patients` baseline demographic variables. This study was undertaken to understand the demographic features of GMA responders and nonresponders. Methods: This was a multicenter study in China involving four institutions and 34 patients with active UC. Baseline conventional medications were continued without changing the dosage. The treatment efficacy was evaluated based on the endo-scopic activity index and the Mayo score. Results: Thirty of the 34 patients completed all 10 GMA treatment sessions. The overall efficacy rate was 70.59%. The receiver operating characteristic analysis showed that the area under the curve was approximately 0.766 for a Mayo score of ≤5.5 with 0.273 specificity and 0.857 sensitivity (Youden index, 0.584) for GMA responders. No GMA-related serious adverse events were observed. Conclusions: The overall efficacy of GMA in patients with active UC who were taking first-line medications or were corticosteroid refractory was encouraging. Addition-ally, GMA was well tolerated and had a good safety profile. (Gut Liver 2017;11:216-225)
An Optimized Motion Estimation Algorithm and Application in the FRUC System
Min-Jun Deng,Ping Gan,Zhuo Chen,Xiao-Qing Shen,Dong-Lian Li,Ming-Yan Yu,Yu Zhang,Cai -Lan Zeng,He Huang 보안공학연구지원센터 2015 International Journal of Multimedia and Ubiquitous Vol.10 No.8
Based on the optimized three-step search algorithm. Combining threshold judgment as well as local full search, a more efficient motion estimation algorithm is proposed. The algorithm not only inherited the traditional three-step algorithm’s quick speed but also kept the advantages of a relatively small amount of calculation, besides it can avoid the local optimum problem in the three-step search algorithm (TSS). In addition, the algorithm combined with the threshold judgment and local full search algorithm, so it also maintains satisfactory visual quality. Comparing the algorithm with TSS and local full search algorithm (LFS). The algorithm has great performance in search points and peak signal-to-noise ratio. Experimental results show that compared with LFS, search points drop by 34.61% ~ 54.47% .While compared with the TSS, the search points only rise by 6.15% ~ 12.21%. The average PSNR of proposed Algorithm is 0.24dB higher than LFS and 3.30dB higher than TSS.
특발성혈소판감소성자반증이 합병된 임신에서 임신부와 신생아의 예후
박유나 ( Yu Na Park ),김세은 ( Sei Eun Kim ),정경란 ( Kyung Lan Jung ),민정애 ( Jung Ae Min ),최석주 ( Suk Joo Choi ),오수영 ( Soo Young Oh ),김종화 ( Jong Hwa Kim ),노정래 ( Cheong Rae Roh ) 대한산부인과학회 2007 Obstetrics & Gynecology Science Vol.50 No.7
목적: 본원에서 분만한 특발성혈소판감소성자반증 (ITP)이 합병된 임신의 주산기 예후 및 신생아 혈소판감소증의 예측 인자를 규명하고자 하였다. 연구 방법: 1994년 10월부터 2006년 10월까지 본원에서 분만한 임신부 중 ITP가 합병된 32명 임신부 및 신생아의 의무기록을 후향적으로 분석하였다. 결과: 본 연구에서 ITP는 1,000 분만 당 0.87의 발생률을 보였고 총 32명중에서 임신 중 처음 ITP를 진단 받은 경우는 12예 (37%)였으며 5만/mm3 이하의 혈소판감소증을 보였던 경우가 59%였다. 대상 임신부의 68.7%에서 혈소판 수치의 회복을 위하여 치료를 시행하였으며 분만 시 5만/mm3 이상의 혈소판 수치의 유지를 위하여 20예 (62.5%)에서 혈소판을 수혈 받았다. 치료 방법으로는 스테로이드 투여가 8예 (25%), immunoglobulin 치료 2예 (6.2%), 스테로이드와 immunoglobulin의 병합치료 6예 (18.7%), anti-Rh (anti-D) 1예 (3.1%)로 나타났다. ITP에 대한 치료를 시행받은 군에서 치료에 대한 반응은 77%에서 나타났다. 출생 후 신생아에게서 5만/mm3 이하의 혈소판감소증이 있었던 경우는 14.2%였으며 이들 모두 immunoglobulin 치료를 받았다. 신생아에서 두개내 출혈 등의 합병증은 1예에서 나타났고 신생아의 혈소판 수치는 분만전의 임신부의 혈소판 수치 및 ITP 진단 시기나 치료 여부와 상관 관계가 없었다 (Spearman correlation coefficient, 0.04; P=0.86). 결론: ITP가 합병된 임신의 경우 신생아의 혈소판감소증은 10%에서 나타나지만 아직까지 이에 대한 예측인자가 규명되지 않은 상태이다. Objective: To investigate the maternal and neonatal outcomes in pregnancies complicated with idiopathic thrombocypenic purpura (ITP) and to identify antenatal factors to predict the neonatal thrombocytopenia. Methods: We analyzed retrospectively maternal and neonatal outcomes of the32 pregnant women with ITP who were delivered over a 12-year period. Results: The prevalence incidence of ITP in pregnancy was 0.87 per 1,000 live births in this study population. The diagnosis of ITP was made more before pregnancy than with afterduring during pregnancy (63% vs 37%). Maternal platelet transfusion was done in 62.5 % of pregnancies with ITP. Sixty nine percent of pregnancies with ITP received medical therapies; steroid only in 8 cases (25%), steroid + IVIG (intravenous immunoglobulin) in 6 cases (18.7%), IVIG only in 2 cases (6.2%), and steroid + IVIG + anti-Rh (anti-D) in 1 case (3.1%). Overall response rate (Plt > 50×109/L) to medical treatment was 77%. Neonatal thrombocytopenia (Plt < 50×109/Ll) was observed seen in 4 cases (14.2%) immunoglobulin. There was no correlation between the maternal and the neonatal platelet count. Moreover medical treatment during pregnancy did not make any difference in neonatal platelet count. There was one case of neonatal ICH (germinal matrix hemorrhage). Conclusion: Although neonatal thrombocytopenia occurred in 140% of pregnancies with ITP, no antenatal factor could predict neonatal thrombocytopenia.
Let-7c Inhibits NSCLC Cell Proliferation by Targeting HOXA1
Zhan, Min,Qu, Qiang,Wang, Guo,Liu, Ying-Zi,Tan, Sheng-Lan,Lou, Xiao-Ya,Yu, Jing,Zhou, Hong-Hao Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.1
Objective: The aim of the present study was to explore mechanisms by which let-7c suppresses NSCLC cell proliferation. Methods: The expression level of let-7c was quantified by qRT-PCR. A549 and H1299 cells were transfected with let-7c mimics to restore the expression of let-7c. The effects of let-7c were then assessed by cell proliferation, colony formation and cell cycle assay. Mouse experiments were used to confirm the effect of let-7c on tumorigenicity in vivo. Luciferase reporter assays and Western blotting were performed to identify target genes for let-7c. Results: HOXA1 was identified as a novel target of let-7c. MTS, colony formation and flow cytometry assays demonstrated that forced expression of let-7c inhibited NSCLC cell proliferation by inducing G1 arrest in vitro, consistent with inhibitory effects induced by knockdown of HOXA1. Mouse experiments demonstrated that let-7c expression suppressed tumorigenesis. Furthermore, we found that let-7c could regulate the expression of HOXA1 downstream effectors CCND1, CDC25A and CDK2. Conclusions: Collectively, these results demonstrate let-7c inhibits NSCLC cell proliferation and tumorigenesis by partial direct targeting of the HOXA1 pathway, which suggests that restoration of let-7c expression may thus offer a potential therapeutic intervention strategy for NSCLC.